Background <p>Anti-programmed cell death protein 1 (PD-1) immunotherapy has revolutionized the treatment of stage III and IV melanoma. Real-world data on its resistance is needed to facilitate the development of combinatorial approaches to overcome anti-PD-1 resistance.</p> Objectives <p>To characterize anti-PD-1 resistance and assess whether progressive disease assigned by clinicians is concordant with scan data assessed by independent central reviewers (ICR).</p>…
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study
Journal for ImmunoTherapy of Cancer | | Gaughan, E. M., Kim, M., Mendez, I., Rao, A. D., Wei, M., So, A., Zhong, X., Berking, C., Jiang, R., Kim, T. M., Dalle, S., Robert, C., Danson, S., Alam, S., Charles, J., Davies, T., Debus, D., Dzienis, M., Frazer, R., Gebhardt, C., Geidel, G., Hassel, J. C., Hansen, I., Heppt, M. V., Hildebrandt, L., Isaacs, J. M., Suh, K. J., Keam, B., Kim, Y. J., Lesimple, T., Saiag, P., Delibes, A., Barnett, R., Krepler, C., Gandhi, K., Qizilbash, N., Shui, I. M., Tan, X.-L., Sullivan, R. J.
Topics: skin-cancer, immunotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer